Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16177346 | 0.82 | ALDH1A1 (0.41) | KDM4EALDH1A1KMT2AHTTL3MBTL1 | |
| SCHEMBL16177237 | 0.79 | CNR2 (0.46) | KDM4EALDH1A1KMT2AHTTTDP1 | |
| SCHEMBL2212203 | 0.77 | L3MBTL1 (0.39) | KDM4EALDH1A1KMT2AHTTL3MBTL1 | |
| SCHEMBL68535 | 0.77 | PDE10A (0.41) | KDM4EALDH1A1KMT2AHTTL3MBTL1 | |
| SCHEMBL1432563 | 0.75 | HTT (0.43) | KDM4EKMT2AHTTL3MBTL1POLB | |
| SCHEMBL7449090 | 0.75 | KMT2A (0.36) | KDM4EALDH1A1KMT2AHTTL3MBTL1 | |
| SCHEMBL13982923 | 0.75 | GAA (0.36) | KMT2AHTTL3MBTL1POLBMAPT | |
| SCHEMBL1357879 | 0.75 | HTT (0.50) | HTTL3MBTL1POLBGAASMN1; SMN2 | |
| SCHEMBL1431321 | 0.75 | HTT (0.53) | KDM4EALDH1A1KMT2AHTTMAPT | |
| SCHEMBL15897830 | 0.75 | NPC1 (0.44) | KDM4EALDH1A1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| EP-4192814-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-07 | — | — | EP | disclosed |
| CN-117616011-A | Inhibitors of transglutaminase | 策迪拉有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-113354677-B | Acrylonitrile compound and preparation method and application thereof | 华中师范大学 | 2023-08-01 | — | — | CN | disclosed |
| EP-4192814-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023275337-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| CN-113354677-A | Acrylonitrile compound and preparation method and application thereof | 华中师范大学 | 2021-09-07 | — | — | CN | disclosed |
| CN-106957317-B | Novel pyrazole derivatives | 持田制药株式会社 | 2019-12-31 | — | — | CN | disclosed |
| WO-2018089493-A1 | PYRROLE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-9816992-B2 | Compositions and methods relating to Lyme disease | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-11-14 | — | — | US | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20130210809-A1 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | BOLEA CHRISTELLE (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013110026-A1 | COMPOSITIONS AND METHODS RELATING TO LYME DISEASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (US) | 2013-07-25 | — | — | WO | disclosed |
| EP-2566858-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | Pfizer Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-7316931-B2 | Mass defect labeling for the determination of oligomer sequences | TARGET DISCOVERY, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-6686373-B2 | ANALGESICS; ANTIINFLAMMATORY AGENT | WARNER-LAMBERT COMPANY LLC | 2004-02-03 | — | — | US | disclosed |
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | KAWAMURA KIYOSHI (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1310498-A2 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PFIZER INC. (US) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PRKCB, PRKCA, PRKCG | KDM4E 1349/4885ALDH1A1 3069/4885KMT2A 1579/4885 |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | KDM4E 967/4885ALDH1A1 1825/4885KMT2A 988/4885 |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | KDM4E 4418/4885ALDH1A1 4135/4885KMT2A 2450/4885 |
| US-20130210809-A1 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM4, GRM1 | KDM4E 1472/4885ALDH1A1 2554/4885KMT2A 1336/4885 |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, ACVR1 | KDM4E 528/4885ALDH1A1 143/4885KMT2A 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.